Gas6 and soluble MerTK in gum disease
Evaluation of Gas6 and Soluble MerTK Levels in Gingival Crevice Fluid in Individuals With Periodontal Health, Gingivitis, and Periodontitis
This project will test whether levels of Gas6 and soluble MerTK in gum fluid and blood are different in adults with periodontitis, gingivitis, or healthy gums.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Abant Izzet Baysal University Academic / other |
| Locations | 1 site (Bolu, Bolu) |
| Trial ID | NCT07535177 on ClinicalTrials.gov |
What this trial studies
This observational study enrolled 90 adults divided into three equal groups: stage III grade B periodontitis, gingivitis, and periodontally healthy individuals. Whole-mouth and site-specific clinical periodontal measures (probing depth, clinical attachment level, bleeding on probing, gingival index, plaque index) were recorded. Gingival crevicular fluid and blood serum were collected and levels of Gas6 and soluble MerTK were measured by enzyme-linked immunosorbent assay (ELISA). Data were compared across groups using non-parametric statistical tests.
Who should consider this trial
Good fit: Adults 18 or older with at least 16 natural teeth, who are non-smokers, free of systemic or infectious diseases, and who fit one of the clinical categories (periodontitis, gingivitis, or healthy gums) are the ideal candidates.
Not a fit: People who currently smoke, are pregnant or lactating, have systemic illnesses, recent antibiotic use or recent periodontal treatment, or have fewer than 16 natural teeth would be excluded and are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, identifying differences in Gas6 and soluble MerTK could point to useful biomarkers for diagnosing or staging periodontal disease.
How similar studies have performed: Related work has linked the Gas6/MerTK pathway to inflammation control in other tissues, but there is limited prior evidence specifically linking these markers to human periodontal disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals without systemic diseases that may affect periodontal tissues (such as cardiovascular diseases, atherosclerosis, immune system disorders, rheumatoid arthritis, obesity, cancer, and diabetes) * Individuals who have not used antibiotics within the last 3 months * Individuals not taking any medications known to affect periodontal tissues * Individuals without infectious diseases such as HIV, hepatitis B virus (HBV), or tuberculosis * Individuals with at least 16 natural teeth, excluding third molars * Individuals aged 18 years and older Exclusion Criteria: * Pregnant or lactating individuals * Individuals who have received periodontal treatment within the last 6 months * Current smokers
Where this trial is running
Bolu, Bolu
- Bolu Abant Izzet Baysal University Faculty of Dentistry — Bolu, Bolu, Turkey (Türkiye) (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.